LabEx IGO

Certified in 2021 by the investments for the future programm (PIA), the LabEx IGO "Immunotherapy-Graft-Oncology" has been extended for 5 years (2020 – 2024) after an evaluation by an international board of examiners. Since the 1st January 2020, the LabEx is headed by Emmanuel Scotet (CRCINA) and Régis Josien (CRTI). Currently, the LabEx IGO gathers about 400 people (scientists, students, technical staff) from 15 research teams located in 4 academic research units (UMR1232, UMR1064, UMR1236, UMR1227) of the French large-western region (Nantes, Angers, Rennes, Brest). The LabEx IGO aims at developing an ambitious translational immunology program that brings together immunologists experts in the fields of immuno-oncology, transplantation and autoimmune fields to develop innovative immunotherapies with enhanced efficacy. The research roadmap of the LabEx is structured in 3 research workpackages (WP): • WP1. New immune markers and therapeutic targets for immunomodulating or depleting therapies; • WP2. Innovative cellular immunotherapies; • WP3. New immunodepleting and immunomodulating strategies with broader indications and enhanced efficacy. The LabEx IGO promotes technological developments allowing high definition analysis of immunity system with (1) imaging technology :purchase of an Akoya Codex in Nantes (25 markers) and of an Fluidigm Hyperion in Brest (50 markers) or (2) Cytometry technology : purchase of a flow cytometry system allowing the analysis of 25 flurorescent markers at the same time in Nantes.

LabEx IGO